Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amycretin Effect on Oral Contraceptive PK and Gastric Emptying
NCT06461039Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Jun 2024
- Primary completion
- Mar 2025
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of amycretin in obesity and Overweight, sponsored by Novo Nordisk. Primary endpoints: Area under the ethinylestradiol plasma concentration time curve at steady state at Day 193 and Area under the levonorgestrel plasma concentration time curve at steady state at Day 193. Started Jun 2024; status: completed.
02
Drugs
amycretin
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT06461039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06461039.